Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: An independent indicator of favourable prognosis in breast cancer

A. Chang, G. M. Yousef, A. Scorilas, L. Grass, P. Sismondi, R. Ponzone, E. P. Diamandis

Research output: Contribution to journalArticle

Abstract

Kallikreins are a group of serine proteases with diverse physiological functions. KLK13 (previously known as KLK-L4) is a novel kallikrein gene located on chromosome 19q13.4 and shares a high degree of homology with other kallikrein family members. Many kallikrein genes were found to be differentially expressed in various malignancies, and their regulation is controlled by steroid hormones in prostate and breast cancer cell lines. We studied the expression of KLK13 by quantitative reverse transcriptase-polymerase chain reaction in 173 patients with epithelial breast carcinoma. An optimal cutoff point equal to the 40th percentile was defined, based on the ability of KLK13 to predict disease-free survival. KLK13 values were then associated with other established prognostic factors and with disease-free survival and overall survival. Higher positivity for KLK13 expression was found in older, oestrogen receptor positive patients. In univariate analysis, KLK13 expression is a significant predictor of improved disease-free survival and overall survival (P

Original languageEnglish
Pages (from-to)1457-1464
Number of pages8
JournalBritish Journal of Cancer
Volume86
Issue number9
DOIs
Publication statusPublished - May 6 2002

Keywords

  • Breast cancer
  • Human kallikrein 13
  • Kallikreins
  • Prognostic and predictive markers
  • Quantitative PCR
  • Serine proteases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: An independent indicator of favourable prognosis in breast cancer'. Together they form a unique fingerprint.

  • Cite this